复宏汉霖(02696)：修订就汉斯状®与ABBOTT及KGBIO的许可协议

Group 1 - The company, Fuhong Hanlin (02696), announced a revised and partially terminated agreement with KGBio to terminate exclusive licensing rights for products in regions outside of Indonesia [1] - The company has also amended its licensing agreement with Abbott to expand the licensing area and milestone payment terms for licensed products, including the regions previously terminated with KGBio [1] - The termination of the commercial collaboration with KGBio allows the company to grant exclusive commercialization rights for the licensed products in the newly added regions to Abbott, enhancing the company's international market reach and product recognition [1]